

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

701826-052310

U.S. APPLICATION NO. (If known, see 37 CFR 1.5

10/019,467

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/CA00/00775

06/28/2000

06/29/1999

TITLE OF INVENTION

HUMAN ALPHA 1,2-MANNOSIDASE

APPLICANT(S) FOR DO/EO/US HERSCOVICS, Annette, A. and TREMBLAY, Linda O.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected (Article 31).
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A preliminary amendment.
14. ☐ An Application Data Sheet under 37 CFR 1.76.
15. ☐ A substitute specification.
16. ☐ A power of attorney and/or change of address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13^{ter}.2 and 37 CFR 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:
Transmittal (PTO-1390); COPY - Notification of Missing Requirements; Declaration and Power of Attorney for Annette Herscovics and Linda Tremblay; Sequence Listing Statement; Amendment Under CFR 1.825; Sequence Listing; Computer Diskette (Sequence Listing); Petition for Extension of Time; Check in the Amount of \$205.00 for Petition of Extension of Time; Express Mail Certificate - EV175417328US; Return Receipt Postcard

21. ☐ The following fees are submitted:

CALCULATIONS PTO USE ONLY

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO **\$1060.00**International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO **\$900.00**International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$750.00**International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) **\$720.00**International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) **\$100.00****ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$

Surcharge of **\$130.00** for furnishing the oath or declaration later than 30 months
from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	-20 =		x \$18.00	\$
Independent claims	-3 =		x \$84.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$

TOTAL OF ABOVE CALCULATIONS =

\$

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above
are reduced by 1/2.

+

\$

SUBTOTAL =

\$

Processing fee of **\$130.00** for furnishing the English translation later than 30 months
from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE =

\$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +

\$

TOTAL FEES ENCLOSED =

\$ 205.00

Amount to be
refunded:

\$

charged:

\$

- a. ☒ A check in the amount of \$ 205.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 50-0850. A duplicate copy of this sheet is enclosed.
(charge fee deficiencies)
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a)
or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

David S. Resnick
Nicole L.M. Valtz
Nixon Peabody LLP
101 Federal Street
Boston, MA 02110

SIGNATURE

David S. Resnick/Nicole L.M. Valtz
NAME

34,235/47,150

REGISTRATION NUMBER

Practitioner's Docket No.: 701826-052310

IN THE UNITED STATES RECEIVING OFFICE (RO/US)

<u>PCT/CA00/00775</u>	<u>06/28/2000</u>	<u>06/29/1999</u>
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
<u>HUMAN ALPHA 1,2-MANNOSIDASE</u>		
TITLE OF INVENTION		
<u>HERSCOVICS, Annette, A. and TREMBLAY, Linda O.</u>		
APPLICANT(S)		

Box PCT (US/RO)
Assistant Commissioner for Patents
Washington, D.C. 20231

VERIFIED CERTIFICATION OF EXPRESS MAILING DATE
(INTERNATIONAL APPLICATION (37 C.F.R. SECTION 1.10(c))

I declare that, on February 21, 2003, I deposited, with the United States Postal Service, in an envelope "Express Mail, Post Office to Addressee," bearing Label Number EV175417328US, addressed to the "Assistant Commissioner for Patents, Washington, D.C. 20231," and having an express mail certification that I executed, the following papers:

A copy of these papers from the file of this application is attached.

Transmittal Form (PTO-1390) (2 pp.);
 Petition for Extension of Time Under 37 CFR 1.136(a) (1 pg.)
 COPY – Notification of Missing Requirements (2 pp.);
 Declaration and Power of Attorney for Annette Herscovics and Linda Tremblay (3 pp.);
 Sequence Listing Statement (2 pp.);
 Amendment Under CFR §1.825 (1 pg.);
 Sequence Listing (8 pp.);
 Computer diskette (Sequence Listing);
 Check in the Amount of \$205.00;
 Express Mail Certificate – EV175417328US (1 pg.); and
 Return Receipt Postcard.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Melissa Kruggel
 (typed or printed name of person making this verified



Signature of person making this verified statement